Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk Adapted De-Intensification of Radio-Chemotherapy for Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma Based on HPV Subtype and Plasma Circulating Free HPV DNA Level and Clearance Rate

NCT05268614 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT05268614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05268614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk Adapted De-Intensification of Radio-Chemotherapy for Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma Based on HPV Subtype and Plasma Circulating Free HPV DNA Level and Clearance Rate
Lead sponsor
University of Florida
Phase
Phase 2
Overall status
Recruiting
Start date
May 16, 2022
Completion date
June 30, 2032
Enrollment
250 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

oropharyngeal squamous cell carcinoma